Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ETTX Entasis Therapeutics (ETTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Entasis Therapeutics Stock (NASDAQ:ETTX) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Get Entasis Therapeutics alerts:Sign Up Key Stats Today's Range$2.19▼$2.1950-Day Range$2.18▼$2.2052-Week Range$1.40▼$3.88Volume800 shsAverage Volume239,104 shsMarket Capitalization$104.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewEntasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.Read More… The most serious warning of my career (Ad)With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now. Receive ETTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ETTX Stock News HeadlinesHedge Fund and Insider Trading News: D.E. Shaw, Elliott Management, Millennium Management, Marshall Wace LLP, Three Arrows Capital, Entasis Therapeutics Holdings Inc. (ETTX), Gossamer Bio Inc (GOSS), and MoreJuly 18, 2022 | insidermonkey.comEntasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.November 5, 2024 | Porter & Company (Ad)Entasis Therapeutics Presents Data on Sulbactam-Durlobactam and ETX0462 at 2022 ASM Microbe Annual ConferenceJune 9, 2022 | finance.yahoo.comINVESTIGATION ALERT: Halper Sadeh LLP Investigates MANT, ETTX, CTEKJune 9, 2022 | apnews.comScott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTXJune 3, 2022 | apnews.comSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates ETTX, CDEV, CTEKMay 31, 2022 | apnews.comBiotech Stock Roundup: ETTX Up on Acquisition Deal, REGN Offers UpdatesMay 25, 2022 | finance.yahoo.comSee More Headlines ETTX Stock Analysis - Frequently Asked Questions How were Entasis Therapeutics' earnings last quarter? Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). When did Entasis Therapeutics IPO? Entasis Therapeutics (ETTX) raised $75 million in an initial public offering on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers. What other stocks do shareholders of Entasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entasis Therapeutics investors own include Sorrento Therapeutics (SRNE), VYNE Therapeutics (VYNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), CymaBay Therapeutics (CBAY), Dynavax Technologies (DVAX) and Pfizer (PFE). Company Calendar Last Earnings11/04/2021Today11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ETTX CUSIPN/A CIK1724344 Webwww.entasistx.com Phone(781) 810-0120FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,140,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-145.48% Return on Assets-103.75% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$7 million Price / Sales14.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.66 per share Price / Book3.32Miscellaneous Outstanding Shares47,852,000Free Float44,742,000Market Cap$104.80 million OptionableNot Optionable Beta1.33 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ETTX) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredNASDAQ small cap that could be gearing up for a massive short squeeze.A Heavy Short Interest Could Lead to a Monstrous Short Squeeze for this Tiny NASDAQ Healthcare Firm!Huge Alerts | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entasis Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entasis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.